Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East


IRVINE, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven biotechnology company specializing in diagnostics technology and test development for cancer detection, today announced the strategic partnership, in commercializing HelioLiver Dx in Saudi Arabia, with Halub Medical Co., a healthcare company for Saudi Arabia, GCC and Middle East. The test is expected to be commercially available in Saudi Arabia and The Gulf Cooperation Council (GCC) in Q1 2025, with the following 12-month revenue for Helio expected to exceed $10 million dollars.

See original here:
Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East

Related Posts